12 May 2016 - It is looking likely that patients with the most common form of lung cancer will not be able to access treatment with Bristol-Myers Squibb’s immunotherapy Opdivo on the National Health Service in England and Wales.

NICE has published draft guidelines turning down the drug’s use in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed after prior chemotherapy.

BMS says the rejection comes despite the offer of several schemes to make Opdivo (nivolumab) more cost effective in the lung cancer setting, including funding treatment after the first year.

For more details, go to: http://www.pharmatimes.com/Article/16-05-12/NICE_turns_down_Opdivo_for_lung_cancer.aspx